Explore

TrendlineTrendline
Global Arrayed CRISPR Screening Market Projected to Reach $3.43 Billion by 2030 Amidst Precision Drug Discovery Demand

Global Arrayed CRISPR Screening Market Projected to Reach $3.43 Billion by 2030 Amidst Precision Drug Discovery Demand

Global Arrayed CRISPR Screening Market Projected to Reach $3.43 Billion by 2030 Amidst Precision Drug Discovery Demand
TrendlineTrendline
Macrogen Launches Next-Generation Spatial Transcriptome Analysis Service in Asia

Macrogen Launches Next-Generation Spatial Transcriptome Analysis Service in Asia

Macrogen Launches Next-Generation Spatial Transcriptome Analysis Service in Asia
Rapid ReadRapid Read
Roche Advances Next-Generation Sequencing in Asia Pacific with AXELIOS 1 Launch

Roche Advances Next-Generation Sequencing in Asia Pacific with AXELIOS 1 Launch

Roche is expanding its next-generation sequencing (NGS) initiatives in the Asia Pacific region following the global introduction of its AXELIOS 1 platform in June 2026. Building on initial adoption in South Korea, Roche plans to bring this advanced technology closer to researchers and laboratory leaders through 'AXELIOS Days' events scheduled for November in Sydney, Australia, and Seoul, South Korea. The AXELIOS 1 platform utilizes Roche's proprietary sequencing by expansion (SBX) technology, which is designed to offer flexibility and high performance across various sequencing workflows. This technology converts genetic information into synthetic molecules called Xpandomers, which are approximately 50 times longer than original DNA fragments, enhancing sequencing accuracy. The platform also boasts high-speed processing, capable of completing sequencing runs in approximately 15 minutes to four hours and generating at least 1.8 terabases in a four-hour run, with the potential for same-day whole-genome sequen...
TrendlineTrendline
Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials
Rapid ReadRapid Read
U.S. FDA Approves 16 New Personalized Therapies for Rare Diseases in 2023, Signaling Growth in Precision Medicine

U.S. FDA Approves 16 New Personalized Therapies for Rare Diseases in 2023, Signaling Growth in Precision Medicine

The U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, a significant increase from six approvals in 2022. This surge in approvals highlights a growing trend towards personalized medicine, which tailors treatments to individual patients based on their unique genetic characteristics, disease susceptibility, and predicted drug response. Beyond rare diseases, the 2023 approvals also included seven cancer therapies and three treatments for other conditions. This shift is driving the demand for genome annotation services, which convert raw genetic data into clinically actionable information to guide diagnosis, treatment selection, and therapeutic development. The global genome annotation services market is projected to reach $2.75 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.9%. Key drivers for this growth include increased demand for personalized medicine research, the adoption of AI-powered bioinformatics platforms, and stronger ...
Rapid ReadRapid Read
Pharmacogenomics Advances Personalized Medicine by Linking Genetics to Drug Response

Pharmacogenomics Advances Personalized Medicine by Linking Genetics to Drug Response

Pharmacogenomics is an evolving field that studies how an individual's genetic makeup influences their response to medications. This scientific discipline aims to move healthcare beyond a trial-and-error approach by using genetic information to predict how a patient will react to specific drugs. By analyzing genetic variations, doctors can potentially identify more suitable medications and dosages, thereby reducing adverse side effects and improving treatment efficacy. This approach is particularly beneficial in areas such as antidepressant prescriptions, cardiovascular treatments, and cancer therapies. While not every prescription requires or benefits from pharmacogenomic testing, it offers a more personalized method for healthcare providers to tailor medical treatments to individual patient characteristics. The integration of genomic real-world data, which links genetic information with clinical outcomes from routine care, is crucial for advancing this field. This data allows researchers to connect DNA v...
Rapid ReadRapid Read
Dr. Drew Weissman's Discoveries in mRNA Technology Lead to Nobel Prize and New Therapeutic Applications

Dr. Drew Weissman's Discoveries in mRNA Technology Lead to Nobel Prize and New Therapeutic Applications

Dr. Drew Weissman, an American physician and immunologist, was awarded the 2023 Nobel Prize in Physiology or Medicine alongside Katalin Karikó for their discoveries concerning RNA modifications that enabled effective mRNA vaccines against COVID-19. Weissman's career began with studies on HIV interactions with immune cells before he collaborated with Karikó in the late 1990s, leading to their seminal 2005 study on modified nucleosides and immune recognition. Their work continued, demonstrating the advantages of incorporating pseudouridine into mRNA for greater protein production and biological stability, and later addressing issues of double-stranded RNA contaminants. Beyond COVID-19, Weissman has contributed to research on mRNA Zika vaccines and a universal influenza vaccine. His work also extends to cell reprogramming, with studies using mRNA to generate temporary CAR T cells for cardiac fibrosis and delivering mRNA to hematopoietic stem cells for conditions like sickle-cell disease. He is a founding scie...
TrendlineTrendline
Precision for Medicine Seeks Resource Manager to Optimize Oncology Development Pathway

Precision for Medicine Seeks Resource Manager to Optimize Oncology Development Pathway

Precision for Medicine Seeks Resource Manager to Optimize Oncology Development Pathway
TrendlineTrendline
3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification

3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification

3billion and DeepLife Announce AI Drug Discovery Collaboration to Enhance Therapeutic Target Identification
Rapid ReadRapid Read
Merck and Moderna's Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence by 42% in Trial

Merck and Moderna's Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence by 42% in Trial

A personalized mRNA cancer vaccine, developed by Merck and Moderna, has demonstrated a 42% reduction in the risk of melanoma recurrence or death when combined with the immunotherapy drug Keytruda, compared to Keytruda alone. This experimental treatment, known as intismeran autogene, is a therapeutic vaccine tailored for individual patients with an existing cancer diagnosis. It functions by analyzing a tumor sample to identify genetic mutations that produce abnormal proteins (neoantigens) and then creating an mRNA treatment to stimulate an immune response against these specific cancer cell characteristics. The Phase 3 INTerpath-001 clinical trial involved over 1,100 high-risk melanoma patients whose tumors had been surgically removed. After a median follow-up of 24.6 months, the combination therapy also reduced the relative risk of cancer spreading to distant parts of the body or death by 38%. The detailed findings were announced on October 22, 2026, as part of the European Society for Medical Oncology (ESM...
Rapid ReadRapid Read
University of Utah Honors Innovation in Biomaterials, Medical Devices, and Sustainable Technologies at 2026 Awards

University of Utah Honors Innovation in Biomaterials, Medical Devices, and Sustainable Technologies at 2026 Awards

The University of Utah's Technology Licensing Office has announced the winners of its 2026 Innovation Awards, recognizing significant advancements across various fields. Fluidx, a medical device company, received the 'Startup of the Year' award for its gel embolic platform, which completed a multinational pivotal trial for blocking blood flow during minimally invasive procedures. Minna Roh-Johnson and Dan Greiner were named 'Founders of the Year' for CaLycia Bioscience, focusing on cancer treatments using engineered immune cells. Zak Fang earned the 'Lifetime Achievement Award' for his Hydrogen-Assisted Magnesiothermic Reduction (HAMR) process, offering a new route to titanium production. Ravi Chandran was recognized as 'Innovator of the Year' for his work on niobium-based alloys for extreme heat and stress applications. Robin Shaw received the 'Breakthrough of the Year' for gene therapy technology aimed at repairing failing heart muscle cells. Jessica Swanson was named 'Investigator on the Rise' for devel...
Rapid ReadRapid Read
CRISPR Therapeutics Reports Positive Phase 1b Results for CTX310 in Severe Hypertriglyceridemia

CRISPR Therapeutics Reports Positive Phase 1b Results for CTX310 in Severe Hypertriglyceridemia

CRISPR Therapeutics has announced positive Phase 1b clinical trial results for its investigational gene-editing therapy, CTX310, designed to treat severe hypertriglyceridemia (sHTG). The data, presented at the American Heart Association (AHA) Scientific Sessions 2026, showed a mean 63% reduction in triglycerides (TG) and a 65% reduction in circulating angiopoietin-like protein 3 (ANGPTL3) at Day 30 following a single-course treatment. Participants in the trial had a median baseline triglyceride concentration exceeding 1,000 mg/dL, indicating significant lipid abnormalities. All ten patients in the Phase 1b cohort had diabetes, 30% had a history of pancreatitis, and 20% had existing atherosclerotic cardiovascular disease, and all had failed prior triglyceride-lowering therapies. The therapy works by permanently disabling the ANGPTL3 gene in liver cells using CRISPR-Cas9 technology, which prevents the production of functional ANGPTL3 protein. This allows lipoprotein lipase (LPL), an enzyme that breaks down t...